Epilepsy
Drug research and approvals for epilepsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 359 studies of epilepsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 37 drug trials for it since 2013, FDA has 2 approved and 16 open orphan designations naming it, and the EU has 27 authorised medicines for it.
- Recruiting worldwide: 359
- Trials authorized in Canada: 37
- FDA orphan approvals: 2
- EU medicines: 27
Recruiting Now
Newest start dates first, of 359 recruiting on ClinicalTrials.gov ↗- Why Do People With Epilepsy Get More Infections?NCT07903168 · Not reported · University of Aberdeen · starts Nov 4, 2026
- Biomarker Targeted Stimulation for Epileptiform EventsNCT06424977 · Not applicable · Cadence Neuroscience · starts Nov 1, 2026
- Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable.NCT07923097 · Phase 1 · Rapport Therapeutics Inc. · starts Nov 1, 2026
- The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic…NCT07507240 · Not applicable · University Hospital, Toulouse · starts Oct 29, 2026
- Overnight TI in TLENCT07434986 · Not applicable · Duke University · starts Oct 15, 2026
- Combined CM and STN Stimulation for Motor EpilepsyNCT07458217 · Not applicable · Boston Scientific Corporation · starts Oct 13, 2026
- Sleep, Music, And Research Trial 2.0NCT07696442 · Not applicable · National Taiwan University Hospital · starts Oct 1, 2026
- Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory ReactivityNCT07249034 · Not applicable · Hospices Civils de Lyon · starts Oct 1, 2026
- A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related DisordersNCT07847918 · Phase 2 · Scripps Translational Science Institute · starts Oct 1, 2026
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyNCT07723963 · Phase 2 / Phase 3 · Jazz Pharmaceuticals · starts Sep 18, 2026
Trials Authorized in Canada
The 10 newest of 37; search them all in Canada trials| Jun 16, 2026 | A parallel-group, phase 2, double-blind, placebo-controlled, randomized study of the safety and efficacy of oral av078 in participants with tuberous sclerosis…AV078 | AEOVIAN PHARMACEUTICALS INC | Ongoing |
| Jul 29, 2025 | A triple-blind, placebo-controlled, randomized clinical trial of cannabinoids for drug resistant epilepsy in adults and childrenMPL-015 (CANNABIDIOL (CBD)) / MPL-016 (DELTA-9-TETRAHYDROCANNABINOL… | UNIVERSITY OF MANITOBA | Pending |
| Apr 14, 2025 | A phase 3, open-label study to investigate the long-term safety and efficacy of lp352 in the treatment of seizures in children and adults with developmental…BEXICASERIN (LP352) | LONGBOARD PHARMACEUTICALS, INC. | Ongoing |
| Mar 21, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of lp352 in the treatment of…BEXICASERIN (LP352) | LONGBOARD PHARMACEUTICALS, INC. | Ongoing |
| Jan 14, 2025 | A pilot, triple-blind, placebo-controlled, randomized clinical trial of cannabinoids for drug resistant epilepsy in adults and childrenMPL-010 (CANNABIDIOL) / MPL-011 (DELTA-9-TETRAHYDROCANNABINOL) | UNIVERSITY OF MANITOBA | Closed |
| May 24, 2024 | Model-informed precision dosing (mipd) in neonates-prospective feasibility trialFOSPHENYTOIN/ ENOXAPARIN | THE HOSPITAL FOR SICK CHILDREN | Pending |
| Dec 28, 2023 | Ferumoxytol enhanced hippocampal vascular imaging in epilepsyFERUMOXYTOL | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Ongoing |
| May 24, 2023 | A phase 3, open-label study of adjunctive ganaxolone (gnx) treatment in children and adults with tuberous sclerosis complex (tsc)-related epilepsy (trusttsc…GANAXOLONE | MARINUS PHARMACEUTICALS, INC. | Closed |
| Mar 9, 2023 | A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the safety, tolerability, and efficacy of xen1101 as adjunctive therapy…AZETUKALNER (XEN1101) | XENON PHARMACEUTICALS INC | Ongoing |
| Jul 8, 2022 | A phase 3, double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone (gnx) treatment in children and adults with tuberous sclerosis complex…GANAXOLONE | MARINUS PHARMACEUTICALS, INC. | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 18| Oct 7, 2016 | CARNEXIVReplacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following… | Lundbeck LLC | Approved |
| Jul 29, 1997 | DiastatFor the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require… | Valeant Pharmaceuticals | Approved |
| Oct 23, 2024 | antrafeninetreatment of KCNT1-related epilepsy | UniSA Ventures Pty Ltd | Designated |
| Sep 25, 2024 | Anti-epileptic small molecule inhibitor of KCNT1treatment of KCNT1-related Epilepsy | Actio Biosciences | Designated |
| May 17, 2023 | (5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopro…Treatment of progressive myoclonic epilepsy-7 | Autifony Therapeutics Ltd. | Designated |
| Jan 19, 2022 | flunarizineTreatment of Juvenile Absence Epilepsy (JAE) | Xenon Pharmaceuticals Inc. | Designated |
| Jun 7, 2021 | cannabidiol oral solution (CBD-OS)Treatment of epilepsy with myoclonic-atonic seizures | Jazz Pharmaceuticals Research UK Limited | Designated |
| May 12, 2021 | flunarizineTreatment of Childhood Absence Epilepsy | Xenon Pharmaceuticals Inc. | Designated |
| Dec 3, 2019 | brivaracetamTreatment of Juvenile Absence Epilepsy | UCB, Inc. | Designated |
| Dec 3, 2019 | brivaracetamTreatment of Childhood Absence Epilepsy | UCB, Inc. | Designated |
| Aug 15, 2019 | cannabidiolTreatment of childhood absence epilepsy | Benuvia Operations LLC | Designated |
| Dec 14, 2017 | metforminTreatment of progressive myoclonus epilepsy type 2 (Lafora disease) | Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) | Designated |
| Nov 10, 2016 | diazepamTreatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require… | Aquestive Therapeutics | Designated |
| Mar 24, 2015 | ganaxoloneTreatment of Protocadherin 19 (PCDH19) female epilepsy. | Immedica Pharma AB | Designated |
| Jul 24, 2013 | topiramate injectionTreatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being… | CURx Pharmaceuticals, Inc. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 27Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA